The clinical utility index as a practical multiattribute approach to drug development decisions.
We identify some innovative approaches to predicting overall patient benefit from investigational drugs to support development decisions. We then illustrate calculation of a probabilistic clinical utility index (CUI), an implementation of multiattribute utility that focuses on clinical attributes. We recommend use of the CUI for the support of early drug development decisions because of its practicality, reasonable accuracy, and transparency to decision makers, at stages in which financial factors that may dominate later-phase decisions are less critical.
Poland
B
B
Pharsight Corporation, Strategic Consulting Services, Mountain View, California, USA.
Hodge
F L
FL
Khan
A
A
Clemen
R T
RT
Wagner
J A
JA
Dykstra
K
K
Krishna
R
R
D003657:Decision Making; D055808:Drug Discovery / Q000379:methods* / Q000592:standards; D004345:Drug Industry / Q000379:methods* / Q000592:standards; D006801:Humans